PHARMACY

McKesson ideaShare 2018 highlights big opportunities for independents
McKesson ideaShare 2018, held in Las Vegas through July 12, has offered myriad opportunities for community pharmacists to improve their knowledge, performance and profitability while networking with industry experts.
Mylan expands central nervous system portfolio with generic Exelon patch
Mylan has received the green light from the Food and Drug Administration for a generic version of Novartis’ Exelon Patch (rivastigmine transdermal system).

Lupin receives FDA nod for generic Plaquenil tablets

The product’s market size for the 12 months ended April 2018 was $215.3 million, according to IQVIA data.
Teva launches generic Uceris

Teva has introduced generic Uceris (budesonide) extended-release tablets, 9 mg, which is indicated for the induction of remission in patients with active, mild-to-moderate ulcerative colitis.
Kantar Consulting to host 2-day workshop

Kantar Consulting is readying for its two-day Health & Wellness and Drug Channel Workshops, which will take place July 25 and 26 at the W Hoboken.
HIV-prevention vaccine candidate shows promise in human trials

A series of preventative HIV vaccine regimens have been evaluated in a study of uninfected human volunteers in five countries.
McKesson ideaShare 2018 highlights new Health Mart Atlas PSAO

Health Mart Atlas is only three months old, and already its PSAO partnership with American Pharmacy Cooperative Inc. is helping its independent pharmacies deal with the changes and complexities of managed care, experts said from ideaShare 2018.
Inovio’s MERS vaccine yields positive results in Phase 1 study

Inovio’s MERS vaccine generated high levels of antibodies and induced broad-based T cell responses in Phase 1 study.
Teva to move U.S. home base to Parsippany-Troy Hills, N.J.

The decision follows approval of a 10-year, $40 million tax incentive plan that was designed to lure Teva to the Garden State. The plan required Teva to keep 1,000 New Jersey jobs to reap the credits.
Catalent acquires Juniper Pharmaceuticals

Catalent, a leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, is acquiring Juniper Pharmaceuticals.